Navigation Links
InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Date:7/23/2008

SAN FRANCISCO, July 23 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug candidate rC3-1 for the treatment of the rare chronic blood disorder paroxysmal nocturnal hemoglobinuria (PNH). The complete results will be presented at the XXII International Complement Workshop in Basel, Switzerland, September 28, 2008.

The only treatment currently available for PNH patients is an anti-C5 antibody Soliris(TM) (eculizumab) sold by Alexion Pharmaceuticals, Inc.

rC3-1 promotes the enzymatic partial depletion of C3, the hub of the complement cascade. Complement protein C3 is the master regulator of complement protein C5 that mediates cell damage in PNH patients. The reduction of C3 has been shown to reduce PNH cell destruction.

PNH is a rare debilitating and life-threading disease. PNH is an acquired genetic blood disorder in which patients' red blood cells are destroyed by complement, a component of the body's immune system. PNH patients have a sub-population of red blood cells (PNH cells) that are susceptible to immune complement-mediated destruction. In this study, PNH cells from patients remained intact in blood serum treated with rC3-1 when compared to non-treated serums.

"rC3-1 appears to be a promising new treatment alternative with several benefits over the existing treatment," Commented Bill St. John CEO of InCode. "The unique action of rC3-1, offers patients the potential for more convenient self-administered dosing and physicians' a more cost effective and flexible treatment option."

InCode is planning PNH clinical trials testing rC3-1. These trials will provide a foundation for series of subsequent clinical trials addressing macular degeneration, asthma and other autoimmune and inflammatory disease indications.

InCode BioParmaceutics, Inc. is an emerging biotechnology company that is developing a new class of recombinant proteins for the controlled depletion of complement protein C3. The therapeutic potential for C3 depletion has been demonstrated in Macular Degeneration, Asthma, Rheumatoid Arthritis, and autoimmune and inflammatory diseases. C3 depletion has also been demonstrated as a useful adjuvant to surgery, transplantation and cancer therapy. InCode is pursuing a progressive clinical development plan focused on proof of concept trials.


'/>"/>
SOURCE InCode BioPharmaceutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental Implants ... ... for Dental Implants in US$ Million. The report provides separate comprehensive analytics ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through 2022. ...
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News ... ... publisher of cannabis market research, the legal cannabis market is ... through 2021, despite conflicting signals from the current presidential administration. ... that the two biggest drivers of growth in this industry ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Deep ... to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 report examines ... deep learning solutions within the healthcare domain. Primarily driven by the ... solution to generate relevant insights from medical data. ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... “End Time GPS”: a dauntless and enlightened study ... Time GPS” is the creation of published author, Wesley Gerboth, a World War II ... and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon ...
(Date:3/24/2017)... ... , ... “The Communion of Saints: A Pastor’s Potpourri of ... across the United States. “The Communion of Saints” is the creation of ... congregations in seven states throughout his long career of devotion to the church. ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World ... that there could be four million Zika-related cases in the Americas within the next ... of US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The physicians of ... in the greater Houston Area. The new location is located at 2255 E. Mossy ... in Springwoods Village. This newest location will provide patients living in the north Houston ...
(Date:3/23/2017)... New Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... a new clinic, located at 960 Gruene Road in Building 2. The clinic is ... co-owner Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings ...
Breaking Medicine News(10 mins):